

TAMPERE UNIVERSITY OF TECHNOLOGY

MOLECULAR DYNAMICS SIMULATIONS OF NEBIVOLOL COMPLEXED WITH B1 AND B2 ADRENERGIC RECEPTORS SUBTYPE SPECIFICITY STUDIES

<u>K. Kaszuba^{1,2}, I. Vattulainen^{2,3,4}, M. Karttunen⁵, and T. Róg²</u>

1Department of Physics and Biophysics, University of Warmia and Mazury, Olsztyn, Poland; **2**Department of Physics, Tampere University of Technology, Finland; **3**Laboratory of Physics and Helsinki Institute of Physics, Helsinki University of Technology, Finland; 4MEMPHYS-Center for Biomembrane Physics, University of Southern Denmark, Odensee, Denmark; 5Department of Applied Mathematics, The University of Western Ontario, London (ON), Canada.

INTRODUCTION

Beta-adrenergic receptors

(ADRBs or βRs) are the membrane proteins which belong to G-protein-coupled receptors (GPCR) family. There are two major subtypes: ADRB1 and ADRB2 which share 60% of overall sequence identity. In the trasmembrane region identity reaches ~80% - high sequence conservatism.

Beta-adrenergic antagonists

(β-blockers) are the class of drugs which play an important role in the treatment of various cardiovascular diseases including hypertension, cardiomyopathy and congestive heart failure. Beta-antagonists interact with beta-adrenergic receptors. The overall effects of their action lead to lowering of blood pressure.

50 ADRB2_HUMAN 50 ADRB2_HUMAN	
50 ADRB2_HUMAN	MGAGVLVLGASEPGNLSSAAPLPDGAATAARLLVPASPPASLLPPASESPEPLSQQWTAGMGLLMALTV
50 ADRB2_HUMAN	LAIVFGNVLVITATAKFERLQTVTNYFITSLACADLVMGLAVVPFGAAHILMKMWTFGNFWCEFWTSID
50 ADRB2_HUMAN	LAIVFGNVLVITATAKFERLOTVTNYFITSLACADLVMGLAVVPFGAAHILMKMWTFGNFWCEFWTSID
88 ADRB1_HUMAN	LLIVAGNVLVIVAIAKTPRLQTLTNLFIMSLASADLVMGLLVVPFGATIVVWGRWEYGSFFCELWTSVD
50 ADRB2_HUMAN	VLCVTASIETLCVIAVDRYFAITSPFKYQSLLTKNKARVIILMVWIVSGLTSFLPIQMHWYRAT - HQEA
50 ADRB2_HUMAN	VLCVIASIEILCVIAVDKYFA IISPFKYQSLLIKNKARVIILMVWIVSGLISFLPIQMHWYRAT - HQEA
88 ADRB1_HUMAN	VLCVTASIETLCVIALDRYLA ITSPFRYQSLLTRAR ARGLVCTVWAISALVSFLPILMHWWRAE - SDEA
50 ADRB2_HUMAN	INCYANETCCDFFTNOAYAIASSIVSFYVPLVIMVFVYSRVFQEAKROLOKIDKSEGRF
50 ADRB2_HUMAN	I NCYANET CCDFFTNQAYAIASSIVSFYVPLVIMVFVYSRVFQEAKROLQKIDKSEGRF
88 ADRB1_HUMAN	RRCYNDPKCCDFVTNRAYAIASSVVSFYVPLCIMAFVYLRVFREAQKQVKKIDSCERRFLGGPARPPSP
50 ADRB2_HUMAN	HVQNLSQVEQDGRTGHGLRRSSKF-CLKEHKALKTLGIIMGIFILCWLPFFI
50 ADRB2_HUMAN	HVQNLSQVEQDGRTGHGLRRSSKF-CLKEHKALKTLGIIMGTFTLCWLPFFI
88 ADRB1_HUMAN	SPSPVPAPAPPPGPPRPAAAA ATAPLANGRAGKRRPSRLVALREQKALKTLGIIMGVFTLCWLPFFL
50 ADRB2_HUMAN	VNIVHVIQDNLIRKEVYILLNWIGYVNSGFNPLIYCR SPDFRIAFQELLCLRRSSLKAYGNGYSSNGN-
50 ADRB2_HUMAN	VNIVHVIQDNLIRKEVYILLNWIGYVNSGFNPLIYCRSPDFRIAFQELLCLRRSSLKAYGNGYSSNGN-
88 ADRB1_HUMAN	ANVVKAFHRELVPDRLFVFFNWLGYANSAFNPIIYCRSPDFRKAFQRLLCCARRAARRHATHGDRPRA
50 ADRB2_HUMAN	<mark>TGEQSGYHVEQEKEN</mark> <mark>KLLCEDLPGT EDF VGHQGT VP S</mark> <mark>DN I D S</mark> - <mark>QG RNC S TND S LL</mark>
50 ADRB2_HUMAN	TGEQSGYHVEQEKEN KLLCEDLPGT EDF VGHQGT VP S DN I D S - QG RNC S TND S LL
88 ADRB1_HUMAN	SGCLARPGPPPSPGAASDDDDDVVGAT PPARLLEPWAGCNGGAAADSDSSLDE - PCRPG FASE S KV
50 ADRB2_HUMAN 50 ADRB2_HUMAN 88 ADRB1_HUMAN	

Sequence alignment of ADRB1 and ADRB2. Helices are highlighted in red and orange, loop regions in green. Conservative residues are colored in blue.





in white, oxygens in red, nitrogens in blue, fluorine in green.

METHOD

Procedure

Nebivolol was docked into the binding sites of ADRB2 and ADRB1

The docked complexes were energy minimized

The lowest energy configurations of nebivolol complexed with ADRB1 and ADRB2 were submitted to molecular dynamics simulation

✤ 3 MD simulations of nebivolol complexed with ADRB1 and 3 MD simulations of nebivolol complexed with ADRB2 were performed

System description

System composition: receptor protein, drug molecule, lipid, water, ions

Size of the systems: $ADRB2 - 120\ 000\ atoms$, ADRB1 – 190 00 atoms

AIM OF THIS WORK

The work discussed here constitutes a part of computational studies which address the problem of ADRB1 selectivity which is of essential importance in treatment of hypertension. The specificity for subtype ADRB1 is one the key properties which contributes to the antihypertensive profile of various β -blockers. Here we are presenting the results which relate to nebivolol – the most ADRB1 selective agent among all available β -blockers.



Non-bonded interactions around the nebivolol in the binding pocket of ADRB1. PHE residues colored in purple, VAL in brown, ILE in green, TRP in silver – residues shown in surface representation. Nebivolol molecule is drawn in licorice model and also represented as transparent surface.

0.5

500

with ADRB1 and ADRB2.

CONCLUSIONS

1. A high sequence conservatism (see sequence alignment) in the binding cavities (helix area) of ADRB1 and ADRB2 suggests a similar binding pattern.

2. Indeed a detailed analysis of the interactions



RMSD value in simulations performed



Simulation parameters

Software: NAMD

Forcefield: CHARMM CMAP forcefield for protein and CHARMM 27 for lipid

- Simulation length: each repeat 30ns
- Temperature: 310K
- Target pressure: 1bar

RESULTS

Structure stability of simulated receptors

RMSD value (calculated for backbone atoms) in simulations performed with ADRB2 was ~2A, the complexes of ADRB1 exhibited more flexibility – RMSD was ~3A

Hydrogen bonds

✤ ~50% of detected h-bonds between nebivolol and receptor proteins relate to

- sequence conservative ASP residue in helix 3
- This residue functions as h-bond acceptor

confirms only a subtle differences in the binding pockets of both simulated subtypes.

3. However we assume that a higher degree of nebivolol selectivity towards ADRB1 subtype is probably caused by higher overall flexibility of ADRB1 molecule which results in more ''relaxed" conformation of the binding site.

4. Accommodation of "stiff" drug molecule into the more spatial and flexible binding pocket of ADRB1 is easier, thus from the energetic point of view more favorable

However a detailed analysis showed that h-bonds in the binding pocket of ADRB1 are stronger and much more stable during dynamics An average number of h-bonds per drug molecule was ~3.5 and ~3 respectively in 2500 1000 1500 2000 3000 trajectory [ps] simulations with ADRB1 and ADRB2

Non-bonded interactions

 $2 \sim 80\%$ of vDW point atom contacts and Pi-Pi stacking interactions related to these same hydrophobic and aromatic residues in the binding sites of both receptors

However the binding pocket of ADRB1 seemed to be more flexible and spatial

Ligand conformation

In case of both simulated receptor subtypes ligand structure was almost equally rigid